# EDGAR Filing Document

**Accession Number:** 0001573785
**File Stem:** 0001193125-26-078718
**Filing Date:** 2026-2
**Character Count:** 10806
**Document Hash:** 1408a3baa560d7e07b4a933f0c2c6827
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-078718.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001193125-26-078718

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260224

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Davidson Michael H.
- **CENTRAL INDEX KEY:** 0001573785

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41562
- **FILM NUMBER:** 26692212

**MAIL ADDRESS:**
- **STREET 1:** C/O BIOAGE LABS, INC.
- **STREET 2:** 5885 HOLLIS STREET, SUITE 370
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewAmsterdam Pharma Co N.V.
- **CENTRAL INDEX KEY:** 0001936258
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC
- **BUSINESS PHONE:** 35 206 2971

**MAIL ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NewAmsterdam Pharma Co B.V.
- **DATE OF NAME CHANGE:** 20220701

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Davidson Michael H.<br><sub>(Last) (First) (Middle)</sub><br>C/O NEWAMSTERDAM PHARMA COMPANY N.V.<br>GOOIMEER 2-35<br><sub>(Street)</sub><br>NAARDEN, P7 1411 DC<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-24 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NewAmsterdam Pharma Co N.V. [ NAMS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2026-02-24 |  | M |  | 64708 | A | <sup>(1)</sup> | 524567 | D |  |
| Ordinary Shares | 2026-02-24 |  | S |  | 61547 | D | 36.13<sup>(2)</sup> | 463020 | D |  |
| Ordinary Shares | 2026-02-24 |  | S |  | 3161 | D | 36.46<sup>(3)</sup> | 459859 | D |  |
| Ordinary Shares | 2026-02-25 |  | M |  | 58253 | A | <sup>(1)</sup> | 518112 | D |  |
| Ordinary Shares | 2026-02-25 |  | S |  | 46517 | D | 35.11<sup>(4)</sup> | 471595 | D |  |
| Ordinary Shares | 2026-02-25 |  | S |  | 10436 | D | 35.96<sup>(5)</sup> | 461159 | D |  |
| Ordinary Shares | 2026-02-25 |  | S |  | 1300 | D | 36.68<sup>(6)</sup> | 459859 | D |  |
| Ordinary Shares | 2026-02-26 |  | M |  | 183332 | A | <sup>(1)</sup> | 643191 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 165408 | D | 33.63<sup>(7)</sup> | 477783 | D |  |
| Ordinary Shares | 2026-02-26 |  | S |  | 17924 | D | 34.44<sup>(8)</sup> | 174144<sup>(9)</sup> | D |  |
| Ordinary Shares |  |  |  |  |  |  |  | 285715<sup>(9)</sup> | I | By GRAT |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Option (right to buy) | <sup>(1)</sup> | 2026-02-24 |  | M |  |  | 64708 | <sup>(10)</sup> | 2031-07-06 | Ordinary Shares | 64708 | $0.00 | 924559 | D |  |
| Option (right to buy) | <sup>(1)</sup> | 2026-02-25 |  | M |  |  | 58253 | <sup>(10)</sup> | 2031-07-06 | Ordinary Shares | 58253 | $0.00 | 866306 | D |  |
| Option (right to buy) | <sup>(1)</sup> | 2026-02-26 |  | M |  |  | 183332 | <sup>(10)</sup> | 2031-07-06 | Ordinary Shares | 183332 | $0.00 | 682974 | D |  |

---

### Footnotes:

(1) The exercise price of the option is EUR 1.16392.

(2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

(3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

(4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

(5) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

(6) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

(7) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

(8) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

(9) The amount reported in Column 5 reflects the transfer of 285,715 ordinary shares from the Reporting Person to the Michael H. Davidson 2026 Grantor Retained Annuity Trust (the "GRAT") on February 26, 2026, which transfer was exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934. The Reporting Person is the sole annuitant and trustee of the GRAT.

(10) The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

**Signature:** /s/ Michael H. Davidson  
**Date:** 2026-02-26

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**